- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001...
Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response...
100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two patients that received three doses...
NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were...
BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first...
Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable...
Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant non-small cell lung cancer (NSCLC)...
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had...
Sydney, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) (Immutep or the...
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in...
Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a...
Brings total Series A funding to over $28 million allowing CyPep-1 to advance into Phase 2 Bergen, Norway, June 2,...
LOS ANGELES, June 01, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce the recipients of...
SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering...
First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate Second dose level initiated in...
Results Add to Growing Body of Evidence that Inhibiting PP2A with LB-100 May Be a General Method for Enhancing the Effectiveness of...
New data show continued durability of response over 14 months with humoral immune responses increasing over time LAWRENCEVILLE, N.J., May...
Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity...
AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...